The patient with the FANCL (head and neck cancer) received olaparib and experienced a TTF for 12 months until progress, whereas the FA patient with CDK4/CCND1 amplification deceased after 13 months, with the first treatment being olaparib (6 months) and then palbociclib (7 months). Here, FANCL is linked to head and neck cancer.